172 related articles for article (PubMed ID: 28664115)
41. Ebselen Is a Potential Anti-Osteoporosis Agent by Suppressing Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Osteoclast Differentiation In vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In vivo.
Baek JM; Kim JY; Yoon KH; Oh J; Lee MS
Int J Biol Sci; 2016; 12(5):478-88. PubMed ID: 27019631
[TBL] [Abstract][Full Text] [Related]
42. (2S)-2'-Methoxykurarinone inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling.
Kim JY; Kim JY; Kim JJ; Oh J; Kim YC; Lee MS
Biol Pharm Bull; 2014; 37(2):255-61. PubMed ID: 24492722
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
[TBL] [Abstract][Full Text] [Related]
44. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
45. Herbacetin inhibits RANKL-mediated osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Li L; Sapkota M; Kim SW; Soh Y
Eur J Pharmacol; 2016 Apr; 777():17-25. PubMed ID: 26923730
[TBL] [Abstract][Full Text] [Related]
46. Ameloblastin attenuates RANKL-mediated osteoclastogenesis by suppressing activation of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1).
Chaweewannakorn W; Ariyoshi W; Okinaga T; Fujita Y; Maki K; Nishihara T
J Cell Physiol; 2019 Feb; 234(2):1745-1757. PubMed ID: 30105896
[TBL] [Abstract][Full Text] [Related]
47. Rubiadin-1-methyl ether from Morinda officinalis How. Inhibits osteoclastogenesis through blocking RANKL-induced NF-κB pathway.
He YQ; Zhang Q; Shen Y; Han T; Zhang QL; Zhang JH; Lin B; Song HT; Hsu HY; Qin LP; Xin HL; Zhang QY
Biochem Biophys Res Commun; 2018 Dec; 506(4):927-931. PubMed ID: 30392907
[TBL] [Abstract][Full Text] [Related]
48. A novel small molecule, NecroX-7, inhibits osteoclast differentiation by suppressing NF-κB activity and c-Fos expression.
Kim HJ; Yoon KA; Lee MK; Kim SH; Lee IK; Kim SY
Life Sci; 2012 Nov; 91(19-20):928-34. PubMed ID: 23000100
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
50. Bu-Shen-Ning-Xin decoction: inhibition of osteoclastogenesis by abrogation of the RANKL-induced NFATc1 and NF-κB signaling pathways via selective estrogen receptor α.
Wang L; Qiu XM; Gui YY; Xu YP; Gober HJ; Li DJ
Drug Des Devel Ther; 2015; 9():3755-66. PubMed ID: 26229438
[TBL] [Abstract][Full Text] [Related]
51. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
52. Effect of BioAggregate on Receptor Activator of Nuclear Factor-Kappa B Ligand-induced Osteoclastogenesis from Murine Macrophage Cell Line In Vitro.
Zhang J; Zhu L; Yan P; Peng B
J Endod; 2015 Aug; 41(8):1265-71. PubMed ID: 25975181
[TBL] [Abstract][Full Text] [Related]
53. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
[TBL] [Abstract][Full Text] [Related]
54. Aminocoumarins inhibit osteoclast differentiation and bone resorption via downregulation of nuclear factor of activated T cells c1.
Zheng T; Noh AL; Park H; Yim M
Biochem Pharmacol; 2013 Feb; 85(3):417-25. PubMed ID: 23123663
[TBL] [Abstract][Full Text] [Related]
55. Mechanisms involved in enhancement of osteoclast formation by activin-A.
Kajita T; Ariyoshi W; Okinaga T; Mitsugi S; Tominaga K; Nishihara T
J Cell Biochem; 2018 Aug; 119(8):6974-6985. PubMed ID: 29737562
[TBL] [Abstract][Full Text] [Related]
56. Inhibitory Effect of
Park KH; Gu DR; Kim MS; Lee SH
J Bone Metab; 2020 Feb; 27(1):53-63. PubMed ID: 32190609
[TBL] [Abstract][Full Text] [Related]
57. WHI-131 Promotes Osteoblast Differentiation and Prevents Osteoclast Formation and Resorption in Mice.
Cheon YH; Kim JY; Baek JM; Ahn SJ; Jun HY; Erkhembaatar M; Kim MS; Lee MS; Oh J
J Bone Miner Res; 2016 Feb; 31(2):403-15. PubMed ID: 26255791
[TBL] [Abstract][Full Text] [Related]
58. The Inhibitory Effect of Angelica tenuissima Water Extract on Receptor Activator of Nuclear Factor-Kappa-B Ligand-Induced Osteoclast Differentiation and Bone Resorbing Activity of Mature Osteoclasts.
Ahn SJ; Baek JM; Cheon YH; Park SH; Lee MS; Oh J; Kim JY
Am J Chin Med; 2015; 43(4):715-29. PubMed ID: 26119955
[TBL] [Abstract][Full Text] [Related]
59. Lumichrome inhibits osteoclastogenesis and bone resorption through suppressing RANKL-induced NFAT activation and calcium signaling.
Liu C; Cao Z; Zhang W; Tickner J; Qiu H; Wang C; Chen K; Wang Z; Tan R; Dong S; Xu J
J Cell Physiol; 2018 Nov; 233(11):8971-8983. PubMed ID: 29904917
[TBL] [Abstract][Full Text] [Related]
60. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
